Sodium Carbonate → HCID 71526354, compound

HRID 1755384Notes

Reaction equation

HRID 1755384 reaction equation
Cl[C:2]1[CH:3]=[C:4]([NH:11][C:12]2[CH:17]=[CH:16][CH:15]=[C:14]([N:18]3[CH2:22][CH2:21][CH2:20][CH:19]3[CH3:23])[N:13]=2)[C:5]2[N:6]([CH:8]=[CH:9][N:10]=2)[N:7]=1.CC1(C)C(C)(C)OB([C:32]2[CH:41]=[C:40]3[C:35]([CH2:36][CH2:37][N:38]([C:42](=[O:44])[CH3:43])[CH2:39]3)=[CH:34][CH:33]=2)O1.CC(C1C=C(C(C)C)C(C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)=C(C(C)C)C=1)C.C([O-])([O-])=O.[Na+].[Na+]>O1CCOCC1.O.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[CH3:23][CH:19]1[CH2:20][CH2:21][CH2:22][N:18]1[C:14]1[N:13]=[C:12]([NH:11][C:4]2[C:5]3[N:6]([CH:8]=[CH:9][N:10]=3)[N:7]=[C:2]([C:32]3[CH:41]=[C:40]4[C:35]([CH2:36][CH2:37][N:38]([C:42](=[O:44])[CH3:43])[CH2:39]4)=[CH:34][CH:33]=3)[CH:3]=2)[CH:17]=[CH:16][CH:15]=1

Participants

8

Reactant 4

HCID 10340Sodium CarbonateHCID 111557942-Dicyclohexylphosphino-2',4',6'-triisoprophylbiphenylHCID 167503971-[7-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl]ethan-1-oneHCID 715343846-chloro-N-(6-(2-methylpyrrolidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine

Product 1

HCID 71526354HCID 71526354, compoundYield 16%

Reagents, catalysts & solvents 3

HCID 9811564Bis(dibenzylideneacetone)palladiumCatalystHCID 962WaterSolventHCID 312751,4-DioxaneSolvent

Conditions

Temperature
100 °C

Procedure

A mixture of 6-chloro-N-(6-(2-methylpyrrolidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine (90 mg, 0.27 mmol), 1-(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethanone (500 mg, crude), Pd2(dba)3 (16 mg, 0.027 mmol), X-phos (26 mg, 0.054 mmol) and Na2CO3 (86 mg, 0.81 mmol) in dioxane (5 mL) and water (5 mL) was heated to 100° C. for 15 h then concentrated in vacuo and purified by prep-HPLC (Gemini 5u C18 150×21.2 mm; inject volume: 3 mL/inj, flow rate: 20 mL/min; wavelength: 214 nm and 254 nm; gradient conditions: 20% acetonitrile/80% water (0.1% TFA, v/v) initially, proceeding to 40% acetonitrile/60% water (0.1% TFA, v/v) in a linear fashion over 9 min) to afford 1-(7-(8-(6-(2-methylpyrrolidin-1-yl)pyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethanone (20 mg, 16%). 1H NMR (300 MHz, CD3OD): δ 8.87-8.83 (m, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.83-7.81 (m, 1H), 7.71-7.48 (m, 2H), 7.34-7.31 (m, 1H), 6.30-6.19 (m, 2H), 4.78-4.74 (m, 2H), 4.26-4.22 (m, 1H), 3.81-3.77 (m, 2H), 3.68-3.62 (m, 1H), 3.46-3.41 (m, 1H), 3.01-2.93 (m, 2H), 2.23 (s, 3H), 2.18-2.02 (m, 3H), 1.88-1.83 (m, 1H), 1.21-1.19 (m, 3H). LC-MS: [M+H]+, 468, tR=1.726 min, HPLC: 96.93% at 214 nm, 99.52% at 254 nm, tR=6.04 min.

Workup

  1. concentrationthen concentrated in vacuo
  2. custompurified by prep-HPLC (Gemini 5u C18 150×21.2 mm

Sources & evidence

ORD record
ord-56c7ed7131174573ae5fd5a8f69ddad4
Source dataset
uspto-grants-2015_10
Patent number
US09169259B2

Reaction notes

Loading…